Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy
- First Online:
- Cite this article as:
- Dalla Vestra, M., Simioni, N. & Masiero, A. Int Urol Nephrol (2009) 41: 119. doi:10.1007/s11255-008-9490-0
Evidence from recent studies indicates that in patients with diabetic nephropathy combined therapy with ACE inhibitors (ACEI) and AT1-receptor antagonists (ARB) results in more complete blockade of the renin–angiotensin–aldosterone system (RAS) than monotherapy, and reduces proteinuria. Most of these trials, however, had short follow-up, included a small number of patients, and were heterogeneous, so the opportunity to start this treatment in these patients remains unclear. This review summarizes the results of these studies, describing the renal effects of dual RAS blockade in both type 1 and type 2 diabetic patients.